These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 31081930

  • 1. 7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma.
    Yin S, Qiu Y, Jin C, Wang R, Wu S, Liu H, Koo S, Han L, Zhang Y, Gao X, Pang X, Wang T, Yu H.
    Int J Cancer; 2019 Dec 15; 145(12):3334-3346. PubMed ID: 31081930
    [Abstract] [Full Text] [Related]

  • 2. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
    Yao S, Ye J, Yin M, Yu R.
    Cancer Lett; 2020 Jul 28; 483():87-97. PubMed ID: 32268165
    [Abstract] [Full Text] [Related]

  • 3. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY.
    Liver Int; 2015 Apr 28; 35(4):1416-29. PubMed ID: 25066210
    [Abstract] [Full Text] [Related]

  • 4. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 28; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
    Pei T, Meng Q, Han J, Sun H, Li L, Song R, Sun B, Pan S, Liang D, Liu L.
    Oncotarget; 2016 Jul 12; 7(28):43475-43491. PubMed ID: 27259268
    [Abstract] [Full Text] [Related]

  • 10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 11. Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling.
    Dai H, Li M, Yang W, Sun X, Wang P, Wang X, Su J, Wang X, Hu X, Zhao M.
    Aging (Albany NY); 2020 Jun 12; 12(12):11717-11731. PubMed ID: 32530437
    [Abstract] [Full Text] [Related]

  • 12. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
    Wang R, Yu Z, Chen F, Xu H, Shen S, Chen W, Chen L, Su Q, Zhang L, Bi J, Zeng W, Li W, Huang X, Wang Q.
    Biomed Pharmacother; 2018 Jul 12; 103():1632-1642. PubMed ID: 29864952
    [Abstract] [Full Text] [Related]

  • 13. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
    Yan H, Jung KH, Kim J, Rumman M, Oh MS, Hong SS.
    Biomed Pharmacother; 2018 Feb 12; 98():134-141. PubMed ID: 29253760
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 15. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J.
    Theranostics; 2021 Aug 15; 11(12):6006-6018. PubMed ID: 33897895
    [Abstract] [Full Text] [Related]

  • 16. Dendrobium nobile active ingredient Dendrobin A against hepatocellular carcinoma via inhibiting nuclear factor kappa-B signaling.
    Yu Y, Fan Y, Mei W, Xu X, Chen Y, Zhao Y, Ruan B, Shen Z, Lu Y, Zheng S, Jie W.
    Biomed Pharmacother; 2024 Aug 15; 177():117013. PubMed ID: 38901205
    [Abstract] [Full Text] [Related]

  • 17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 15; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 18. Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy.
    Wang Y, Su L, Hu Z, Peng S, Li N, Fu H, Wang B, Wu H.
    Apoptosis; 2024 Oct 15; 29(9-10):1429-1453. PubMed ID: 39023830
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z.
    Biomed Pharmacother; 2017 Apr 15; 88():421-429. PubMed ID: 28122307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.